biotech · Hypertrophic Cardiomyopathy · Arrhythmogenic Right Ventricular Cardiomyopathy · TNYA
Tenaya Therapeutics
Tenaya Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker TNYA. Primary therapeutic focus areas include Hypertrophic Cardiomyopathy, Arrhythmogenic Right Vent
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2016
- Employees
- 99
- Programs
- 2
- Drugs
- 1
- Patents
- 13
Quick answer
Tenaya Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker TNYA. Primary therapeutic focus areas include Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 13 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (1), phase 1 (1).
Company snapshot
Tenaya Therapeutics is a clinical stage biotechnology company. The Company was founded in 2016 by leading cardiovascular scientists from the David J. Gladstone Institutes and the University of Texas Southwestern Medical Center. We are a biotechnology company committed to a bold mission: to discover, design, develop and deliver curative therapies that address the underlying drivers of heart disease
- 2 active pipeline program(s) linked via ClinicalTrials.gov.
- 13 US patent(s) indexed to this assignee profile.
- 2 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Tenaya Therapeutics. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- trial_data
Tenaya Therapeutics to Present TN-201 Gene Therapy Data for HCM on June 3, 2026
Recent coverage
Top assets
Lead pipeline drugs
- approved
- Phase 2
- Phase 1
Momentum
Proprietary activity score for Tenaya Therapeutics.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Recent activity
Latest pipeline, patent, and corporate events for Tenaya Therapeutics.
- Clinical update
- Clinical update
- Patent grant
- Patent grant
HDAC6 inhibitors for treatment of metabolic disease and HFpEF
- Patent grant
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Tenaya Therapeutics?
-
Is Tenaya Therapeutics publicly traded?
-
What drugs does Tenaya Therapeutics develop or market?
-
What are the latest developments for Tenaya Therapeutics?
-
What therapeutic areas does Tenaya Therapeutics focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.